Log in

NASDAQ:CBMGCellular Biomedicine Group Stock Price, Forecast & News

$12.71
-0.48 (-3.64 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.60
Now: $12.71
$13.46
50-Day Range
$13.13
MA: $14.32
$15.56
52-Week Range
$10.98
Now: $12.71
$18.99
Volume78,889 shs
Average Volume82,436 shs
Market Capitalization$246.45 million
P/E RatioN/A
Dividend YieldN/A
Beta1.58
Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases. The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase I clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a strategic licensing and collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.
Read More
Cellular Biomedicine Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.09 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBMG
CUSIPN/A
Phone347-905-5663

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$340,000.00
Book Value$2.89 per share

Profitability

Net Income$-49,980,000.00

Miscellaneous

Employees193
Market Cap$246.45 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive CBMG News and Ratings via Email

Sign-up to receive the latest news and ratings for CBMG and its competitors with MarketBeat's FREE daily newsletter.

Cellular Biomedicine Group (NASDAQ:CBMG) Frequently Asked Questions

How has Cellular Biomedicine Group's stock been impacted by COVID-19 (Coronavirus)?

Cellular Biomedicine Group's stock was trading at $14.49 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CBMG shares have decreased by 12.3% and is now trading at $12.71. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cellular Biomedicine Group?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cellular Biomedicine Group.

When is Cellular Biomedicine Group's next earnings date?

Cellular Biomedicine Group is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Cellular Biomedicine Group.

How were Cellular Biomedicine Group's earnings last quarter?

Cellular Biomedicine Group Inc (NASDAQ:CBMG) posted its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.76) by $0.18. View Cellular Biomedicine Group's earnings history.

What price target have analysts set for CBMG?

3 brokerages have issued 12 month price targets for Cellular Biomedicine Group's shares. Their forecasts range from $19.00 to $27.00. On average, they anticipate Cellular Biomedicine Group's stock price to reach $21.67 in the next twelve months. This suggests a possible upside of 70.5% from the stock's current price. View analysts' price targets for Cellular Biomedicine Group.

Has Cellular Biomedicine Group been receiving favorable news coverage?

News headlines about CBMG stock have trended neutral on Saturday, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cellular Biomedicine Group earned a coverage optimism score of 0.4 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutCellular Biomedicine Group.

Are investors shorting Cellular Biomedicine Group?

Cellular Biomedicine Group saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 408,700 shares, a drop of 15.3% from the April 30th total of 482,600 shares. Based on an average daily trading volume, of 69,300 shares, the short-interest ratio is currently 5.9 days. Approximately 4.0% of the company's stock are sold short. View Cellular Biomedicine Group's Current Options Chain.

Who are some of Cellular Biomedicine Group's key competitors?

What other stocks do shareholders of Cellular Biomedicine Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellular Biomedicine Group investors own include Crispr Therapeutics (CRSP), Anavex Life Sciences (AVXL), Aduro BioTech (ADRO), Amarin (AMRN), Adaptimmune Therapeutics (ADAP), Exelixis (EXEL), Fate Therapeutics (FATE), ImmunoGen (IMGN), Viewray (VRAY) and Agile Therapeutics (AGRX).

Who are Cellular Biomedicine Group's key executives?

Cellular Biomedicine Group's management team includes the following people:
  • Mr. Bizuo Liu, CEO, CFO & Director (Age 54)
  • Dr. Yihong Yao, Chief Scientific Officer (Age 51)
  • Mr. Andrew K. Chan, Chief Legal Officer, Gen. Counsel, Sr. VP of Corp. Bus. Devel. & Sec. (Age 61)
  • Dr. Li Zhang, Chief Production Officer
  • Derrick C. Li, Head of Strategy & Investor Relations

What is Cellular Biomedicine Group's stock symbol?

Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."

Who are Cellular Biomedicine Group's major shareholders?

Cellular Biomedicine Group's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (4.16%), Nikko Asset Management Americas Inc. (2.46%), Sumitomo Mitsui Trust Holdings Inc. (2.46%), Nikko Asset Management Americas Inc. (2.46%), State Street Corp (1.12%) and Geode Capital Management LLC (0.85%). View institutional ownership trends for Cellular Biomedicine Group.

Which institutional investors are selling Cellular Biomedicine Group stock?

CBMG stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Morgan Stanley, State Street Corp, UBS Group AG, BlackRock Inc., and Vident Investment Advisory LLC. View insider buying and selling activity for Cellular Biomedicine Group.

Which institutional investors are buying Cellular Biomedicine Group stock?

CBMG stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Geode Capital Management LLC, Citigroup Inc., BNP Paribas Arbitrage SA, Russell Investments Group Ltd., and Rhumbline Advisers. View insider buying and selling activity for Cellular Biomedicine Group.

How do I buy shares of Cellular Biomedicine Group?

Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cellular Biomedicine Group's stock price today?

One share of CBMG stock can currently be purchased for approximately $12.71.

How big of a company is Cellular Biomedicine Group?

Cellular Biomedicine Group has a market capitalization of $246.45 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-49,980,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Cellular Biomedicine Group employs 193 workers across the globe.

What is Cellular Biomedicine Group's official website?

The official website for Cellular Biomedicine Group is www.cellbiomedgroup.com.

How can I contact Cellular Biomedicine Group?

Cellular Biomedicine Group's mailing address is 1345 AVENUE OF AMERICAS 15TH FLOOR, NEW YORK NY, 10105. The biotechnology company can be reached via phone at 347-905-5663 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.